ASCEND Study
Welcome to the ASCEND study website. ASCEND is a clinical trial which aimed to find out whether aspirin and/or omega-3 fatty acids (fish oils) reduced the risk of heart attacks and strokes in people with diabetes who did not already have any existing problems with their heart or blood circulation, when they started the study.
We would like to say a big "Thank you!" to all our ASCEND participants for your ongoing support for the study.
Trial began 2005
15480 participants
Follow up until 2017
Study results: fish oils
What's new
ascend eye assessment
Cognitive Function Assessment
ISRCTN registry no: ISRCTN60635500
ClinicalTrials.gov Identifier: NCT00135226
Eudract Number: 2004-000991-15
Please click the following links for ASCEND-EYE Questionnaire and ASCEND-EYE Participant Information Leaflet.
Requests can be made for sharing ASCEND data, with procedures for accessing the data available at: https://www.ndph.ox.ac.uk/data-access.
Learn about our Privacy Notice: ASCEND.
Learn about our Privacy Notice: ASCEND-EYE.
ASCEND is funded by the British Heart Foundation with additional support from Bayer Healthcare and AG Mylan (previously Abbott Laboratories) who provide the study treatments and some funding to cover the drug packaging. Alzheimer’s Research UK have provided a grant to allow the measurement of cognitive function in ASCEND. ASCEND is co-ordinated by CTSU which It is funded by the Medical Research Council as well as by grants from the British Heart Foundation and from Cancer Research UK.